Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role. Mike is an accomplished and highly successful leader, with deep expertise in building market-leading brands, conducting award-winning product launches, creating highly effective teams and developing sound commercial strategies to sustain market leadership.

2492

Braeburn Pharmaceuticals is developing long-acting medicines for treating opioid addiction. The Company's mission is to advance a portfolio of next-generation therapies, with individualized dosing regimens and delivery options, to address the escalating disease burden of addiction faced by patients and healthcare professionals.

Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions. The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by offering 7,692,308 shares of its common stock at $18.00 to $21.00 apiece. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and Braeburn Pharmaceuticals, Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, PRINCETON, NJ, USA & LUND, Sweden I December 15, 2015 I Braeburn Pharmaceuticals and Camurus today announced that the first patient has been enrolled in a Phase 3 clinical trial of CAM2038, long-acting subcutaneous buprenorphine injections for treatment of opioid dependence. The Phase 3 trial is designed to demonstrate the long-term safety and clinical efficacy of CAM2038 weekly and monthly Braeburn Pharmaceuticals will become a division of Apple Tree Consolidated. Braeburn Pharmaceuticals is led by a strong, highly experienced team that includes Rose Crane, former Company Group Chair OTC, Specialty and Nutritionals at Johnson & Johnson, and President, Primary Care at Bristol Myers Squibb, and Garry Neil, M.D., former Group President Pharmaceutical R&D at Johnson & Johnson.

  1. Fotogener
  2. Blocket jobb varmland
  3. Messaure
  4. Kan inte lugna ner mig
  5. Hur gör man en hopper i minecraft
  6. The life coach jacob hellberg
  7. 81181 sandviken

Braeburn Pharmaceuticals, an Apple Tree Partners company, is focused on developing and commercializing new treatment options for serious neuropsychiatric disorders, including addiction, in order to help those whose suffering is compounded by the stigma associated with their disease, and for whom long-acting medicines are particularly beneficial. Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and Braeburn Pharmaceuticals filed plans for a $150 million initial public offering last week with the Securities & Exchange Commission, leaving out any specific pricing details. The Princeton, N.J.-based company plans to list its shares on the Nasdaq market under the symbol "BBRX". JPMorgan, Merrill Lynch and Deustche Bank are underwriters for the offering and Apple… Braeburn's investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and Braeburn Pharmaceuticals and Camurus today announced the expansion of their collaboration and license agreement from 2014 to include buprenorphine combination products. 2017-02-13 PRINCETON, NJ, USA and LUND, Sweden I October 24, 2016 I Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) today announced the expansion of their collaboration and license agreement from 2014 to include buprenorphine combination products. The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in … Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, announced today that they have entered into … Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience.

Camurus. Advancing late stage pipeline Expansive and rewarding pharma partnerships Novartis, Braeburn Pharmaceuticals, Rhythm, Solasia, R-Pharm US.

The first drug candidate within the expanded scope, (CAM2058), is an extended release injectable combination of buprenorphine and granisetron in … Braeburn Pharmaceuticals, Inc. and Knight Therapeutics Inc. , a leading Canadian specialty pharmaceutical company, announced today that they have entered into … Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges.

Braeburn pharmaceuticals pipeline

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a pill-free pharmaceutical Camurus' clinical pipeline includes products for treatment of cancer, 

Titan Pharmaceuticals is in discussions with Braeburn management to more fully understand the current status of Probuphine, including Braeburn’s interactions with the FDA regarding the post-approval clinical requirements, and the possible return of the commercialization rights. Camurus' clinical pipeline represents a healthy mix of in-house and partnered programs from early to late stage development.

Braeburn pharmaceuticals pipeline

har för Camurus amerikanska partner Braeburn Pharmaceuticals aviserat ett  Braeburn Pharmaceuticals and Camurus announces start of; Subject Camurus' clinical pipeline includes products for treatment of cancer,  MILSTOLPAR 2019.
Eva hot

BuzzCatchers. Endokrin – Endokrina körtlar | Cancerfonden. Pipeline | Camurus. Professor Kjell Öberg:  Läkemedel - Drugsmart. Läkemedel och medicinering vid smärtlindring .

We aim to reduce stigma by raising awareness that opioid use disorder (OUD) is a chronic brain disease best managed by evidence-based treatments. Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role.
Var kan jag sälja saker

bokföringskonto 5520
explicit och implicit
rod dagar i sverige
huawei y6 unboxing
import old itunes library

Braeburn is committed to the fight against opioid use disorder. Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities.

The work we are doing can make a difference in the lives of patients who often shoulder the burden of treatment themselves. We aim to reduce stigma by raising awareness that opioid use disorder (OUD) is a chronic brain disease best managed by evidence-based treatments. Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role.


Fyrbodal antagning
privat aktiebolag aktiekapital

Braeburn Pharmaceuticals will become a division of Apple Tree Consolidated. Braeburn Pharmaceuticals is led by a strong, highly experienced team that includes Rose Crane, former Company Group Chair OTC, Specialty and Nutritionals at Johnson & Johnson, and President, Primary Care at Bristol Myers Squibb, and Garry Neil, M.D., former Group President Pharmaceutical R&D at Johnson & Johnson.

Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. About Braeburn Pharmaceuticals Braeburn Pharmaceuticals, an Apple Tree Partners company, is focused on developing and commercializing new treatment options for serious neuropsychiatric disorders, including addiction, in order to help those whose suffering is compounded by the stigma associated with their disease, and for whom long-acting medicines are particularly beneficial. TITAN PHARMACEUTICALS LICENSES EXCLUSIVE PROBUPHINE COMMERCIALIZATION RIGHTS IN U.S. AND CANADA TO BRAEBURN PHARMACEUTICALS Details Category: More News Published on Tuesday, 18 December 2012 13:24 Braeburn | 4,775 followers on LinkedIn. Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of OUD. | Braeburn is dedicated to delivering 2017-02-13 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Princeton, New Jersey and Lund, Sweden — 15 December 2015 — Braeburn Pharmaceuticals and Camurus today announced that the first patient has been enrolled in a Phase 3 clinical trial of CAM2038, long-acting subcutaneous buprenorphine injections for treatment of opioid dependence. PRINCETON, N.J., June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins 2016-09-30 · Princeton, New Jersey and Lund, Sweden — 29 September 2016 — Braeburn Pharmaceuticals and Camurus announce that the first patients have been enrolled in the randomized, double blind, placebo Summary Braeburn Pharmaceuticals Inc (Braeburn), an Apple Tree Partners’ portfolio company, is a specialty pharmaceutical company that develops the novel and long-acting implantable and injectable treatments for the psychiatric and neurological disorders including addiction, schizophrenia and pain. Braeburn Pharmaceuticals announced that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors.